cmcmaster/rheumatology_pbs_schedule · Datasets at Hugging Face

pbs_code stringlengths 5 6	drug stringclasses 15 values	brand stringclasses 29 values	formulation stringclasses 35 values	indication stringclasses 7 values	treatment_phase stringclasses 53 values	streamlined_code stringclasses 33 values	online_application bool 2 classes	authority_method stringclasses 2 values	hospital_type stringclasses 3 values	schedule_code int64 4.03k 4.03k	schedule_year int64 2.02k 2.02k	schedule_month stringclasses 1 value
9458T	etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	psoriatic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9458T	etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	psoriatic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12577Y	infliximab	Remsima SC	Solution for injection 120 mg in 1 mL pre-filled pen	rheumatoid arthritis	Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
10900Q	secukinumab	Cosentyx	Injection 150 mg in 1 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
10900Q	secukinumab	Cosentyx	Injection 150 mg in 1 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
10900Q	secukinumab	Cosentyx	Injection 150 mg in 1 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9104E	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9104E	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9104E	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9104E	adalimumab	Idacio	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9104E	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9104E	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9104E	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9104E	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9104E	adalimumab	Idacio	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9104E	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9104E	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9104E	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9104E	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9104E	adalimumab	Idacio	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9104E	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
13293P	adalimumab	Humira	Injection 20 mg in 0.2 mL pre-filled syringe	juvenile idiopathic arthritis	Continuing treatment	14136	true	STREAMLINED	Public	4,030	2,024	AUGUST
11521J	golimumab	Simponi	Injection 50 mg in 0.5 mL single use pre-filled pen	non-radiographic axial spondyloarthritis	Continuing treatment	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
11521J	golimumab	Simponi	Injection 50 mg in 0.5 mL single use pre-filled pen	non-radiographic axial spondyloarthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
1423X	tocilizumab	Actemra	Concentrate for injection 200 mg in 10 mL	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
1423X	tocilizumab	Actemra	Concentrate for injection 200 mg in 10 mL	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months)	null	true	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
1423X	tocilizumab	Actemra	Concentrate for injection 200 mg in 10 mL	juvenile idiopathic arthritis	Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)	null	true	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
1423X	tocilizumab	Actemra	Concentrate for injection 200 mg in 10 mL	juvenile idiopathic arthritis	Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months)	null	true	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
11743C	tocilizumab	Actemra Subcutaneous Injection	Injection 162 mg in 0.9 mL single use pre-filled syringe	giant cell arteritis	Initial treatment	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12084B	tocilizumab	Actemra ACTPen	Injection 162 mg in 0.9 mL single use pre-filled pen	juvenile idiopathic arthritis	Continuing treatment in a patient weighing at least 30 kg	14088	true	STREAMLINED	Any	4,030	2,024	AUGUST
13345J	tofacitinib	Xeljanz	Tablet 5 mg	ankylosing spondylitis	Continuing treatment	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
13345J	tofacitinib	Xeljanz	Tablet 5 mg	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
13345J	tofacitinib	Xeljanz	Tablet 5 mg	ankylosing spondylitis	Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12795K	tocilizumab	Actemra	Concentrate for injection 200 mg in 10 mL	juvenile idiopathic arthritis	Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab)	null	true	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
12795K	tocilizumab	Actemra	Concentrate for injection 200 mg in 10 mL	juvenile idiopathic arthritis	Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)	null	true	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
13685G	tocilizumab	Actemra Subcutaneous Injection	Injection 162 mg in 0.9 mL single use pre-filled syringe	rheumatoid arthritis	Subsequent continuing treatment	14499	true	STREAMLINED	Any	4,030	2,024	AUGUST
13763J	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled syringe	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
13763J	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled syringe	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
13763J	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled syringe	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
13763J	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled syringe	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
13763J	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled syringe	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
13763J	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled syringe	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12364R	adalimumab	Humira	Injection 40 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12364R	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12364R	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12364R	adalimumab	Humira	Injection 40 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12364R	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12364R	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12364R	adalimumab	Humira	Injection 40 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12364R	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12364R	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12364R	adalimumab	Humira	Injection 40 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12364R	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12364R	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
13332Q	etanercept	Enbrel	Injections 50 mg in 1 mL single use pre-filled syringes, 4	juvenile idiopathic arthritis	Continuing treatment	14155	true	STREAMLINED	Private	4,030	2,024	AUGUST
12625L	upadacitinib	Rinvoq	Tablet 15 mg	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12625L	upadacitinib	Rinvoq	Tablet 15 mg	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12625L	upadacitinib	Rinvoq	Tablet 15 mg	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
12625L	upadacitinib	Rinvoq	Tablet 15 mg	ankylosing spondylitis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9659J	tocilizumab	Actemra	Concentrate for injection 400 mg in 20 mL	rheumatoid arthritis	First continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Public	4,030	2,024	AUGUST
9659J	tocilizumab	Actemra	Concentrate for injection 400 mg in 20 mL	rheumatoid arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	4,030	2,024	AUGUST
9659J	tocilizumab	Actemra	Concentrate for injection 400 mg in 20 mL	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Public	4,030	2,024	AUGUST
9659J	tocilizumab	Actemra	Concentrate for injection 400 mg in 20 mL	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Public	4,030	2,024	AUGUST
9659J	tocilizumab	Actemra	Concentrate for injection 400 mg in 20 mL	rheumatoid arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Public	4,030	2,024	AUGUST
9659J	tocilizumab	Actemra	Concentrate for injection 400 mg in 20 mL	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Public	4,030	2,024	AUGUST
11481G	infliximab	Inflectra	Powder for I.V. infusion 100 mg	rheumatoid arthritis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Public	4,030	2,024	AUGUST
11481G	infliximab	Renflexis	Powder for I.V. infusion 100 mg	rheumatoid arthritis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Public	4,030	2,024	AUGUST
11481G	infliximab	Remicade	Powder for I.V. infusion 100 mg	rheumatoid arthritis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Public	4,030	2,024	AUGUST
1476Q	tocilizumab	Actemra	Concentrate for injection 80 mg in 4 mL	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Public	4,030	2,024	AUGUST
1476Q	tocilizumab	Actemra	Concentrate for injection 80 mg in 4 mL	juvenile idiopathic arthritis	Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months)	null	true	AUTHORITY_REQUIRED	Public	4,030	2,024	AUGUST
1476Q	tocilizumab	Actemra	Concentrate for injection 80 mg in 4 mL	juvenile idiopathic arthritis	Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)	null	true	AUTHORITY_REQUIRED	Public	4,030	2,024	AUGUST
1476Q	tocilizumab	Actemra	Concentrate for injection 80 mg in 4 mL	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months)	null	true	AUTHORITY_REQUIRED	Public	4,030	2,024	AUGUST
10895K	secukinumab	Cosentyx	Injection 150 mg in 1 mL pre-filled pen	psoriatic arthritis	Continuing treatment	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
10895K	secukinumab	Cosentyx	Injection 150 mg in 1 mL pre-filled pen	psoriatic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
6496X	infliximab	Inflectra	Powder for I.V. infusion 100 mg	psoriatic arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
6496X	infliximab	Remicade	Powder for I.V. infusion 100 mg	psoriatic arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
6496X	infliximab	Renflexis	Powder for I.V. infusion 100 mg	psoriatic arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
6496X	infliximab	Inflectra	Powder for I.V. infusion 100 mg	psoriatic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
6496X	infliximab	Remicade	Powder for I.V. infusion 100 mg	psoriatic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
6496X	infliximab	Renflexis	Powder for I.V. infusion 100 mg	psoriatic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
6496X	infliximab	Inflectra	Powder for I.V. infusion 100 mg	psoriatic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
6496X	infliximab	Remicade	Powder for I.V. infusion 100 mg	psoriatic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
6496X	infliximab	Renflexis	Powder for I.V. infusion 100 mg	psoriatic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
6496X	infliximab	Inflectra	Powder for I.V. infusion 100 mg	psoriatic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
6496X	infliximab	Remicade	Powder for I.V. infusion 100 mg	psoriatic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
6496X	infliximab	Renflexis	Powder for I.V. infusion 100 mg	psoriatic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
6496X	infliximab	Inflectra	Powder for I.V. infusion 100 mg	psoriatic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
6496X	infliximab	Remicade	Powder for I.V. infusion 100 mg	psoriatic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
6496X	infliximab	Renflexis	Powder for I.V. infusion 100 mg	psoriatic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
6496X	infliximab	Inflectra	Powder for I.V. infusion 100 mg	psoriatic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
6496X	infliximab	Remicade	Powder for I.V. infusion 100 mg	psoriatic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
6496X	infliximab	Renflexis	Powder for I.V. infusion 100 mg	psoriatic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
11320T	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
11320T	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	ankylosing spondylitis	Continuing treatment	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
11721X	tocilizumab	Actemra Subcutaneous Injection	Injection 162 mg in 0.9 mL single use pre-filled syringe	giant cell arteritis	Continuing treatment	null	true	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST
9615C	etanercept	Enbrel	Injections 50 mg in 1 mL single use pre-filled syringes, 4	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
9615C	etanercept	Enbrel	Injections 50 mg in 1 mL single use pre-filled syringes, 4	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)	null	true	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
9615C	etanercept	Enbrel	Injections 50 mg in 1 mL single use pre-filled syringes, 4	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
9615C	etanercept	Enbrel	Injections 50 mg in 1 mL single use pre-filled syringes, 4	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Private	4,030	2,024	AUGUST
9077R	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled syringe	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	4,030	2,024	AUGUST

9458T

etanercept

Brenzys

Injection 50 mg in 1 mL single use auto-injector, 4

psoriatic arthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9458T

etanercept

Enbrel

Injection 50 mg in 1 mL single use auto-injector, 4

psoriatic arthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12577Y

infliximab

Remsima SC

Solution for injection 120 mg in 1 mL pre-filled pen

rheumatoid arthritis

Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

10900Q

secukinumab

Cosentyx

Injection 150 mg in 1 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

10900Q

secukinumab

Cosentyx

Injection 150 mg in 1 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

10900Q

secukinumab

Cosentyx

Injection 150 mg in 1 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9104E

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

ankylosing spondylitis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9104E

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

ankylosing spondylitis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9104E

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

ankylosing spondylitis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9104E

adalimumab

Idacio

Injection 40 mg in 0.8 mL pre-filled pen

ankylosing spondylitis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9104E

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

ankylosing spondylitis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9104E

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

ankylosing spondylitis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9104E

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

ankylosing spondylitis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9104E

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

ankylosing spondylitis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9104E

adalimumab

Idacio

Injection 40 mg in 0.8 mL pre-filled pen

ankylosing spondylitis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9104E

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

ankylosing spondylitis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9104E

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

ankylosing spondylitis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9104E

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

ankylosing spondylitis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9104E

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

ankylosing spondylitis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9104E

adalimumab

Idacio

Injection 40 mg in 0.8 mL pre-filled pen

ankylosing spondylitis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9104E

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

ankylosing spondylitis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

13293P

adalimumab

Humira

Injection 20 mg in 0.2 mL pre-filled syringe

juvenile idiopathic arthritis

Continuing treatment

14136

true

STREAMLINED

Public

4,030

2,024

AUGUST

11521J

golimumab

Simponi

Injection 50 mg in 0.5 mL single use pre-filled pen

non-radiographic axial spondyloarthritis

Continuing treatment

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

11521J

golimumab

Simponi

Injection 50 mg in 0.5 mL single use pre-filled pen

non-radiographic axial spondyloarthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

1423X

tocilizumab

Actemra

Concentrate for injection 200 mg in 10 mL

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

1423X

tocilizumab

Actemra

Concentrate for injection 200 mg in 10 mL

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months)

null

true

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

1423X

tocilizumab

Actemra

Concentrate for injection 200 mg in 10 mL

juvenile idiopathic arthritis

Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)

null

true

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

1423X

tocilizumab

Actemra

Concentrate for injection 200 mg in 10 mL

juvenile idiopathic arthritis

Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months)

null

true

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

11743C

tocilizumab

Actemra Subcutaneous Injection

Injection 162 mg in 0.9 mL single use pre-filled syringe

giant cell arteritis

Initial treatment

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12084B

tocilizumab

Actemra ACTPen

Injection 162 mg in 0.9 mL single use pre-filled pen

juvenile idiopathic arthritis

Continuing treatment in a patient weighing at least 30 kg

14088

true

STREAMLINED

Any

4,030

2,024

AUGUST

13345J

tofacitinib

Xeljanz

Tablet 5 mg

ankylosing spondylitis

Continuing treatment

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

13345J

tofacitinib

Xeljanz

Tablet 5 mg

ankylosing spondylitis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

13345J

tofacitinib

Xeljanz

Tablet 5 mg

ankylosing spondylitis

Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12795K

tocilizumab

Actemra

Concentrate for injection 200 mg in 10 mL

juvenile idiopathic arthritis

Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab)

null

true

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

12795K

tocilizumab

Actemra

Concentrate for injection 200 mg in 10 mL

juvenile idiopathic arthritis

Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)

null

true

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

13685G

tocilizumab

Actemra Subcutaneous Injection

Injection 162 mg in 0.9 mL single use pre-filled syringe

rheumatoid arthritis

Subsequent continuing treatment

14499

true

STREAMLINED

Any

4,030

2,024

AUGUST

13763J

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled syringe

ankylosing spondylitis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

13763J

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled syringe

ankylosing spondylitis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

13763J

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled syringe

ankylosing spondylitis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

13763J

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled syringe

ankylosing spondylitis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

13763J

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled syringe

ankylosing spondylitis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

13763J

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled syringe

ankylosing spondylitis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12364R

adalimumab

Humira

Injection 40 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12364R

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12364R

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12364R

adalimumab

Humira

Injection 40 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months)

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12364R

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months)

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12364R

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months)

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12364R

adalimumab

Humira

Injection 40 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12364R

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12364R

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12364R

adalimumab

Humira

Injection 40 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12364R

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12364R

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

13332Q

etanercept

Enbrel

Injections 50 mg in 1 mL single use pre-filled syringes, 4

juvenile idiopathic arthritis

Continuing treatment

14155

true

STREAMLINED

Private

4,030

2,024

AUGUST

12625L

upadacitinib

Rinvoq

Tablet 15 mg

ankylosing spondylitis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12625L

upadacitinib

Rinvoq

Tablet 15 mg

ankylosing spondylitis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12625L

upadacitinib

Rinvoq

Tablet 15 mg

ankylosing spondylitis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

12625L

upadacitinib

Rinvoq

Tablet 15 mg

ankylosing spondylitis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9659J

tocilizumab

Actemra

Concentrate for injection 400 mg in 20 mL

rheumatoid arthritis

First continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Public

4,030

2,024

AUGUST

9659J

tocilizumab

Actemra

Concentrate for injection 400 mg in 20 mL

rheumatoid arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

4,030

2,024

AUGUST

9659J

tocilizumab

Actemra

Concentrate for injection 400 mg in 20 mL

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

false

AUTHORITY_REQUIRED

Public

4,030

2,024

AUGUST

9659J

tocilizumab

Actemra

Concentrate for injection 400 mg in 20 mL

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

false

AUTHORITY_REQUIRED

Public

4,030

2,024

AUGUST

9659J

tocilizumab

Actemra

Concentrate for injection 400 mg in 20 mL

rheumatoid arthritis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Public

4,030

2,024

AUGUST

9659J

tocilizumab

Actemra

Concentrate for injection 400 mg in 20 mL

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Public

4,030

2,024

AUGUST

11481G

infliximab

Inflectra

Powder for I.V. infusion 100 mg

rheumatoid arthritis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Public

4,030

2,024

AUGUST

11481G

infliximab

Renflexis

Powder for I.V. infusion 100 mg

rheumatoid arthritis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Public

4,030

2,024

AUGUST

11481G

infliximab

Remicade

Powder for I.V. infusion 100 mg

rheumatoid arthritis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Public

4,030

2,024

AUGUST

1476Q

tocilizumab

Actemra

Concentrate for injection 80 mg in 4 mL

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Public

4,030

2,024

AUGUST

1476Q

tocilizumab

Actemra

Concentrate for injection 80 mg in 4 mL

juvenile idiopathic arthritis

Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months)

null

true

AUTHORITY_REQUIRED

Public

4,030

2,024

AUGUST

1476Q

tocilizumab

Actemra

Concentrate for injection 80 mg in 4 mL

juvenile idiopathic arthritis

Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)

null

true

AUTHORITY_REQUIRED

Public

4,030

2,024

AUGUST

1476Q

tocilizumab

Actemra

Concentrate for injection 80 mg in 4 mL

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months)

null

true

AUTHORITY_REQUIRED

Public

4,030

2,024

AUGUST

10895K

secukinumab

Cosentyx

Injection 150 mg in 1 mL pre-filled pen

psoriatic arthritis

Continuing treatment

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

10895K

secukinumab

Cosentyx

Injection 150 mg in 1 mL pre-filled pen

psoriatic arthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

6496X

infliximab

Inflectra

Powder for I.V. infusion 100 mg

psoriatic arthritis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

6496X

infliximab

Remicade

Powder for I.V. infusion 100 mg

psoriatic arthritis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

6496X

infliximab

Renflexis

Powder for I.V. infusion 100 mg

psoriatic arthritis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

6496X

infliximab

Inflectra

Powder for I.V. infusion 100 mg

psoriatic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

6496X

infliximab

Remicade

Powder for I.V. infusion 100 mg

psoriatic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

6496X

infliximab

Renflexis

Powder for I.V. infusion 100 mg

psoriatic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

6496X

infliximab

Inflectra

Powder for I.V. infusion 100 mg

psoriatic arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

6496X

infliximab

Remicade

Powder for I.V. infusion 100 mg

psoriatic arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

6496X

infliximab

Renflexis

Powder for I.V. infusion 100 mg

psoriatic arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

6496X

infliximab

Inflectra

Powder for I.V. infusion 100 mg

psoriatic arthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

6496X

infliximab

Remicade

Powder for I.V. infusion 100 mg

psoriatic arthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

6496X

infliximab

Renflexis

Powder for I.V. infusion 100 mg

psoriatic arthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

6496X

infliximab

Inflectra

Powder for I.V. infusion 100 mg

psoriatic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

6496X

infliximab

Remicade

Powder for I.V. infusion 100 mg

psoriatic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

6496X

infliximab

Renflexis

Powder for I.V. infusion 100 mg

psoriatic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

6496X

infliximab

Inflectra

Powder for I.V. infusion 100 mg

psoriatic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

6496X

infliximab

Remicade

Powder for I.V. infusion 100 mg

psoriatic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

6496X

infliximab

Renflexis

Powder for I.V. infusion 100 mg

psoriatic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

11320T

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

ankylosing spondylitis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

11320T

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

ankylosing spondylitis

Continuing treatment

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

11721X

tocilizumab

Actemra Subcutaneous Injection

Injection 162 mg in 0.9 mL single use pre-filled syringe

giant cell arteritis

Continuing treatment

null

true

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST

9615C

etanercept

Enbrel

Injections 50 mg in 1 mL single use pre-filled syringes, 4

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

9615C

etanercept

Enbrel

Injections 50 mg in 1 mL single use pre-filled syringes, 4

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

null

true

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

9615C

etanercept

Enbrel

Injections 50 mg in 1 mL single use pre-filled syringes, 4

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

9615C

etanercept

Enbrel

Injections 50 mg in 1 mL single use pre-filled syringes, 4

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Private

4,030

2,024

AUGUST

9077R

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled syringe

ankylosing spondylitis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

4,030

2,024

AUGUST